ASTRAZENECA PLC-SPONS ADR (AZN) Stock Overview
NASDAQ:AZN - US0463531089 - ADR
AZN Key Statistics, Chart & Performance
The current stock price of AZN is 79.9 USD. In the past month the price increased by 8.05%. In the past year, price decreased by -8.81%.
AZN Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.36 | 693.36B | ||
| JNJ | JOHNSON & JOHNSON | 17.72 | 426.69B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 14.48 | 250.88B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.3 | 244.98B | ||
| MRK | MERCK & CO. INC. | 10.92 | 210.11B | ||
| PFE | PFIZER INC | 7.3 | 140.77B | ||
| SNY | SANOFI-ADR | 11.17 | 120.68B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.01 | 96.03B | ||
| GSK | GSK PLC-SPON ADR | 8.8 | 79.92B | ||
| ZTS | ZOETIS INC | 25.14 | 69.31B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 51.69 | 47.34B | ||
| HLN | HALEON PLC-ADR | 20 | 43.93B |
Related stock screener links
About AZN
Company Profile
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The firm focuses on the discovery, development, and commercialization of prescription medicines. The firm operates across therapy areas, including Oncology; Cardiovascular, Renal and Metabolism (CVRM); Respiratory and Immunology (R&I); Vaccines and Immune Therapies (V&I), and Rare Disease. In the Oncology area, its key products include Tagrisso, Imfinzi, Calquence, Lynparza, and Enhertu. The key products of CVRM area include Farxiga/Forxiga, Brilinta/Brilique, Crestor, and Lokelma. In the R&I area, the key products are Symbicort, Fasenra, Breztri/Trixeo, and Tezspire. In the V&I Therapies area, the products are Beyfortus and FluMist. The products in the Rare Disease area are Ultomiris, Soliris, Strensiq, and Koselugo. The company has about 191 projects in its development pipeline, including 19 new molecular entities (NMEs) in the late-stage pipeline. The firm distributes its products in over 125 countries.
Company Info
ASTRAZENECA PLC-SPONS ADR
1 Francis Crick Avenue, Cambridge Biomedical Campus
CAMBRIDGE CAMBRIDGESHIRE CB2 0AA GB
CEO: Pascal Soriot
Employees: 94300
Phone: 442073045000
ASTRAZENECA PLC-SPONS ADR / AZN FAQ
What is the stock price of ASTRAZENECA PLC-SPONS ADR today?
The current stock price of AZN is 79.9 USD. The price decreased by -0.11% in the last trading session.
What is the ticker symbol for ASTRAZENECA PLC-SPONS ADR stock?
The exchange symbol of ASTRAZENECA PLC-SPONS ADR is AZN and it is listed on the Nasdaq exchange.
On which exchange is AZN stock listed?
AZN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ASTRAZENECA PLC-SPONS ADR stock?
34 analysts have analysed AZN and the average price target is 90.96 USD. This implies a price increase of 13.85% is expected in the next year compared to the current price of 79.9. Check the ASTRAZENECA PLC-SPONS ADR stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ASTRAZENECA PLC-SPONS ADR worth?
ASTRAZENECA PLC-SPONS ADR (AZN) has a market capitalization of 247.73B USD. This makes AZN a Mega Cap stock.
How many employees does ASTRAZENECA PLC-SPONS ADR have?
ASTRAZENECA PLC-SPONS ADR (AZN) currently has 94300 employees.
What are the support and resistance levels for ASTRAZENECA PLC-SPONS ADR (AZN) stock?
ASTRAZENECA PLC-SPONS ADR (AZN) has a support level at 78.72. Check the full technical report for a detailed analysis of AZN support and resistance levels.
Is ASTRAZENECA PLC-SPONS ADR (AZN) expected to grow?
The Revenue of ASTRAZENECA PLC-SPONS ADR (AZN) is expected to grow by 9.37% in the next year. Check the estimates tab for more information on the AZN EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy ASTRAZENECA PLC-SPONS ADR (AZN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of AZN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of AZN, evaluating the profitability, health, valuation and growth aspects
- ASTRAZENECA PLC-SPONS ADR (AZN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ASTRAZENECA PLC-SPONS ADR (AZN) Sales and EPS estimates to see what analysts future expectations are.
- ASTRAZENECA PLC-SPONS ADR (AZN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ASTRAZENECA PLC-SPONS ADR (AZN) Insider and Institutional Ownership to learn about the owners and their transactions.
- ASTRAZENECA PLC-SPONS ADR (AZN) Stock Chart to make your own analysis
- ASTRAZENECA PLC-SPONS ADR (AZN) Latest news and press-releases to stay up to date.
Does ASTRAZENECA PLC-SPONS ADR (AZN) stock pay dividends?
ASTRAZENECA PLC-SPONS ADR (AZN) has a dividend yield of 2.07%. The yearly dividend amount is currently 2.99. Check the full fundamental report for a detailed analysis of AZN dividend history, reliability and sustainability.
When does ASTRAZENECA PLC-SPONS ADR (AZN) report earnings?
ASTRAZENECA PLC-SPONS ADR (AZN) will report earnings on 2025-11-06, before the market open.
What is the Price/Earnings (PE) ratio of ASTRAZENECA PLC-SPONS ADR (AZN)?
The PE ratio for ASTRAZENECA PLC-SPONS ADR (AZN) is 18. This is based on the reported non-GAAP earnings per share of 4.44 and the current share price of 79.9 USD. Check the full fundamental report for a full analysis of the valuation metrics for AZN.
What is the Short Interest ratio of ASTRAZENECA PLC-SPONS ADR (AZN) stock?
The outstanding short interest for ASTRAZENECA PLC-SPONS ADR (AZN) is 0.18% of its float. Check the ownership tab for more information on the AZN short interest.
AZN Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to AZN. When comparing the yearly performance of all stocks, AZN is a bad performer in the overall market: 64.35% of all stocks are doing better.
AZN Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to AZN. AZN has an excellent profitability rating, but there are some minor concerns on its financial health.
AZN Financial Highlights
Over the last trailing twelve months AZN reported a non-GAAP Earnings per Share(EPS) of 4.44. The EPS increased by 22.3% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 14.68% | ||
| ROA | 7.38% | ||
| ROE | 18.55% | ||
| Debt/Equity | 0.63 |
AZN Forecast & Estimates
34 analysts have analysed AZN and the average price target is 90.96 USD. This implies a price increase of 13.85% is expected in the next year compared to the current price of 79.9.
For the next year, analysts expect an EPS growth of 13.69% and a revenue growth 9.37% for AZN